Shockwave Medical

106 articles about Shockwave Medical

• Shockwave Medical to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/17/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Shockwave Medical Reports Third Quarter 2021 Financial Results

  11/8/2021

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2021.

• Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy

  11/5/2021

  Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, unveiled new data confirming the safety and effectiveness of coronary IVL out to one year, a new gender analysis that found similar outcomes between men and women, and an OCT analysis that found consistent acute performance in eccentric, concentric and nodular calcified lesions.

• Shockwave IVL Consistently Treats “Real World” Calcium Across Multiple Peripheral Vessel BedsDisrupt PAD III Observational Arm Confirms IVL Safely and Effectively Modifies Superficial and Deep Calcium in Complex Calcified Lesions

  10/6/2021

  Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced that an interim analysis from the Disrupt PAD III Observational Study showed that IVL performs consistently well across challenging peripheral vessels, lesions and patients.

• Shockwave Medical to Participate in Two Upcoming Virtual Investor Conferences

  8/26/2021

  Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced that the company will be participating in two upcoming virtual investor conferences.

• Publications Validate Clinical Safety and Efficacy of Shockwave Intravascular Lithotripsy

  6/28/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), announced today that the safety, efficacy and mechanism of benefit of IVL for the treatment of coronary and peripheral artery disease has been further elucidated with the publication of three separate manuscripts in the June 28, 2021 issue of the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC CI)

• CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave’s Coronary IVLProvides Incremental Reimbursement in Hospital Outpatient Setting

  6/11/2021

  Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced that the Centers for Medicare & Medicaid Services granted approval for a Transitional Pass-Through payment for Shockwave C2 Coronary IVL device, effective July 1, 2021.

• Shockwave Medical Reports First Quarter 2021 Financial Results

  5/10/2021

  Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months ended March 31, 2021.

• Shockwave Medical to Participate in the Bank of America Securities 2021 Health Care Conference

  4/27/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the upcoming Bank of America Securities 2021 Health Care Conference that is being held virtually from May 10-12, 2021.

• CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient CasesNew Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule

  4/27/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare and Medicaid Services (CMS) published the Fiscal Year 2022 Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule,

• Shockwave Medical to Report First Quarter 2021 Financial Results on May 10, 2021

  4/12/2021

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will host a corresponding conferenc

• Shockwave Appoints Sara Toyloy to Board of Directors

  3/25/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Sara Toyloy has joined its Board of Directors and will serve on Shockwave’s Audit Committee.

• Shockwave Announces Joint Venture in ChinaEstablishes a Company to Maximize the Availability of IVL for the Chinese Population

  3/22/2021

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTech Group

• Shockwave Medical Reports Fourth Quarter and Full Year 2020 Financial Results

  2/17/2021

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2020.

• Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease

  2/16/2021

  Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced that the company’s sonic pressure wave therapy received Pre-Market Approval for severely calcified coronary artery disease from the U.S. Food and Drug Administration.

• Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

  1/19/2021

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 17, 2021

• Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the KneeFour New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting

  12/4/2020

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified peripheral and coronary artery disease, announced today that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) has created four new codes for IVL procedures performed in the ti

• Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/18/2020

  Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

• Shockwave Medical Reports Third Quarter 2020 Financial Results

  11/9/2020

  Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020.

• Shockwave IVL Is Superior to Angioplasty in Severely Calcified Peripheral Artery DiseaseDisrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials

  11/7/2020

  Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, reported that investigators unveiled data from the Disrupt PAD III study, which showed IVL to be superior to percutaneous transluminal angioplasty on the primary endpoint of procedural success.